Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "ranibizumab"

14 News Found

DME market across 7MM set to reach $11.1 billion in 2031, forecasts GlobalData
News | September 21, 2022

DME market across 7MM set to reach $11.1 billion in 2031, forecasts GlobalData

Biogen sells equity stake in its biosimilar JV with Samsung Biologics for US $ 2.3 billion
News | January 28, 2022

Biogen sells equity stake in its biosimilar JV with Samsung Biologics for US $ 2.3 billion

The companies will continue with their exclusive agreements, including commercialization of their current portfolio

Roche’s Susvimo, for `wet’ age-related macular degeneration (nAMD) approved
Drug Approval | October 25, 2021

Roche’s Susvimo, for `wet’ age-related macular degeneration (nAMD) approved

The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months

U.S. FDA approves Samsung Bioepis and Biogen’s BYOOVIZ biosimilar
Drug Approval | September 21, 2021

U.S. FDA approves Samsung Bioepis and Biogen’s BYOOVIZ biosimilar

It becomes the first ophthalmology biosimilar to gain FDA approval in the United States

Latest Stories

Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients

Kenvue unleashes science-driven skincare offensive at American Academy of Dermatology meet

Samsung Biologics scores Blbig at 2026 CDMO Leadership Awards

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging